Navigation Links
Auxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2010 Results and Conduct Conference Call on Thursday, February 10, 2011
Date:2/3/2011

n the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's assessments as of any date subsequent to the date of this release.

For More Information, Contact:James E. Fickenscher / CFO

William Q. Sargent, Jr. / V.P., I.R. Auxilium Pharmaceuticals, Inc.

Auxilium Pharmaceuticals, Inc.(484) 321-5900

(484) 321-5900jfickenscher@auxilium.com

wsargent@auxilium.com
'/>"/>

SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vanda Pharmaceuticals to Announce Fourth Quarter 2010 Financial Results on February 10, 2011
2. Onyx Pharmaceuticals Receives Fast Track Designation for Carfilzomib; Company Initiates Rolling NDA Submission for Accelerated Approval
3. Cadence Pharmaceuticals Announces U.S. Launch and Availability of OFIRMEV™ (acetaminophen) Injection
4. Cempra Pharmaceuticals Profiles the Broad Spectrum and Potent Activity Profile of Solithromycin (CEM-101) at the 5th Annual PHEMCE Stakeholders Workshop and BARDA Industry Day
5. Takeda and Zinfandel Pharmaceuticals Sign Licensing Agreement for Alzheimers Disease Biomarker in Combination with Pioglitazone
6. Savient Pharmaceuticals Provides Business Update
7. Anthera Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
8. Anadys Pharmaceuticals Augments Management Team and Board of Directors
9. Isis Pharmaceuticals Adds Two New Drugs to Development Pipeline
10. Onyx Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
11. Keryx Biopharmaceuticals to Present at 29th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2015)... and RARITAN, N.J. , May ... open-label, two-part, single-arm Phase 2 MMY2002 (SIRIUS) trial ... human anti-CD38 monoclonal antibody – achieved an overall ... 20.8-38.9), as assessed by an independent review committee, ... ORR was consistent among the pre-specified subgroups based ...
(Date:5/29/2015)... Norway , May 29, 2015 ... biopharmaceutical company, today announces that an abstract on the ... molecule inhibitor of the Axl receptor tyrosine kinase, and ... at BerGenBio, has been published in conjunction with the ... in Chicago , May 29 - ...
(Date:5/29/2015)... Market Publishers Ltd and Shanghai ... partnership agreement for quality market research promotion on ... sell research reports worked out by Chem-Report. , ... upon the agreement: “Chem-Report is a Chinese company ... chemical markets on global and country levels. The ...
(Date:5/29/2015)... May 29, 2015  Caris Life Sciences ® ... the promise of precision medicine, today announced the ... the clinical utility of Caris Molecular Intelligence ® ... in helping to identify targeted treatment options for ... of the studies, results of which are to ...
Breaking Biology Technology:Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 2Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 3Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 4Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 5Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 6Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 7BGB324 and BGB10C9 Show Promise in Models of Pancreatic Cancer 2BGB324 and BGB10C9 Show Promise in Models of Pancreatic Cancer 3Market Publishers Ltd and Chem-Report Sign Partnership Agreement 2Market Publishers Ltd and Chem-Report Sign Partnership Agreement 3Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 2Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 3Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 4Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 5Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 6
... Cynvec LLC, a privately held biotechnology company focused ... ability of the sindbis viral vector, today announced that ... a presentation titled "Cynvec: Breakthrough Oncolytic Viral Vector Therapy ... on Biotechnology and Pharmaceutical Industry. Mr. Stonebanks, presentation ...
... Pharmaceuticals, a pioneer in the development of novel products ... disease, announced that it has promoted F. Stephen Laroux, ... inflammatory diseases, effective immediately. Dr. Laroux joined the company ... team of Cequent researchers developing drug candidates using Cequent,s ...
... LLC announced today that it has issued an Executive Informational ... full 56-page report can be found at www.crystalra.com ... Company") is a development-stage biotechnology company focused on the discovery ... inactive precursor of a drug that is converted into its ...
Cached Biology Technology:Cynvec to Present at the 11th Annual Shanghai International Forum on Biotechnology and Pharmaceutical Industry 2Cequent Names F. Stephen Laroux, Ph.D., Director, Immunology and Inflammatory Diseases 2Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on GenSpera, Inc. 2Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on GenSpera, Inc. 3
(Date:5/8/2015)... Calif. , May 8, 2015 Synaptics Inc. ... solutions, today announced that members of the executive management team ... Morgan 43rd Annual Technology, Media and Telecom Conference Date: ... Hotel in Boston, MA ... 27, 2015 Time: 2:45pm ET Location: The New York Palace ...
(Date:5/6/2015)... 6, 2015 LifeBEAM, a developer of bio-sensing ... announced today that they will expand their partnership in ... bio-sensing cycling helmet and the first joint project between ... colors in order to give cyclists more style choices ... LifeBEAM and Lazer announced their plan to release a ...
(Date:4/27/2015)... , April 27, 2015  For more than ... trade show has been the premier worldwide event for ... 2015 is a must-attend event for any local, national, ... into the emerging commercial markets and current applications of ... innovations of this projected $48 billion industry, and how ...
Breaking Biology News(10 mins):Synaptics to Present at Upcoming Investor Conferences 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5
... catch more than a cold from certain viruses. Some ... their insides to soup - without harming beneficial insects ... environmentally friendly means of biological crop protection worldwide. The ... has been controlled in European orchards for years with ...
... of the worlds worst pollution problems of the 1970s and ... Europe and North America. In Wales, more than 12,000 ... stream insects and river birds such as the dipper. ... Europe to clean up acid pollutants from power generation and ...
... States participating in the GMES Programme approved the transition ... Component Programme. Oversubscription of the programme by the ... with oversubscription to phase 2 of 116%, giving a ... the programme will allow ESA to confirm the development ...
Cached Biology News:Surprise in the organic orchard -- a healthier worm in the apple 2Recovery from acid rain 'much slower than expected' 2
... Rabbit polyclonal to MLF1 Interacting ... for all tested applications). ... corresponding to amino acids 73-83 of ... Entrez Gene ID: 359815 ...
... Nuclease is a genetically engineered endonuclease. This ... and RNA while having no proteolytic activity. ... of conditions and possesses an exceptionally high ... acids from recombinant proteins, its use enables ...
... handy dispensers save space and organize ... other garb. They are the perfect ... used in labs, processing and manufacturing. ... and the particles they attract. Many ...
... Microarrays designed for genome-wide microRNA ... flexible and powerful Paraflo microfluidic on-chip ... as part of our comprehensive microRNA ... Content The Rice microRNA Microarray ...
Biology Products: